DDMAC Dislike: FDA Cracks Down On Facebook Widget Used On Tasigna Website
This article was originally published in The Pink Sheet Daily
Agency says Novartis' "Facebook Share" items, which users can post on their Facebook walls, must include risk along with efficacy information.
You may also be interested in...
Social Media Monitoring: The Next Frontier In Corp. Integrity Agreements?
Expert questions whether companies could be required to monitor social media posts and search engine results as part of a future corporate integrity agreement.
AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms
Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?
Socially Adept: Pharma Companies Must Proactively Gauge Risk Tolerance For Online Promotions, Experts Advise
Absent formal FDA guidance, pharmaceutical manufacturers must decide how much risk they are willing to take with Internet and social media product promotion and be capable of walking away from certain online venues, panelists say at the FDLI annual meeting.